The RET oncogene was originally created by an accidental in-vivo recombination of two human genes, Ret and RFP (the Ret-finger protein then, known today as TRIM27), during a transformation of the NIH3T3 cells with human lymphoma DNA.1 The founder Ret tran

The mouse brain-tropic RET melanoma-sorted (BT-RMS) cell line is a derivative of the Ret-melanoma sorted cell line (RMS, Cat. No. SCC462). The RMS parental cells were isolated from a spontaneously occurring skin tumor in RET transgenic mice. SCC465 cells were derived from brain tumors formed after intracardiac injection of Ret malanoma-sorted (RMS) cells.

SCC465, the BT-RMS brain-tropic RET melanoma-sorted mouse cell line, expresses mCherry and exhibits increased incidence and shortened timeline of brain metastasis post-subdermal injection.​

BT-RMS cells should be stored in liquid nitrogen until use. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact l

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.